Navigation Links
New Sigma Advanced Genetic Engineering Labs Offers Research Community Unique Rodent Models Developed Using Exclusive Gene-Editing Technology
Date:8/21/2009

ST. LOUIS, Aug. 21 /PRNewswire-FirstCall/ -- Sigma-Aldrich(R) (Nasdaq: SIAL) announced today that scientists at its new Sigma Advanced Genetic Engineering (SAGE(TM)) Labs in St. Louis will leverage its exclusive CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (www.compozrzfn.com) to define, develop and offer a new generation of genetically-engineered rodent research models. Such models are commonly used to study disease states in humans and play a key role in the drug discovery process.

Employing methods used to generate the world's first rat with a targeted gene deletion, commonly referred to as a 'Knockout' as introduced in the July 24, 2009 issue of the Journal Science(R), "Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases", scientists at SAGE Labs will initially create Knockout rat models with focus in toxicology, neuroscience, cardiovascular and inflammatory disease, areas that would benefit most immediately from the promise represented by the availability of the Knockout Rat. Using this novel methodology, Knockout Rats and Mice can be generated in as little as four months, about one-third the time required to make a Knockout model using conventional Embryonic Stem Cell (ES cell) based approaches.

"The Knockout Rat is a long-awaited milestone in the scientific community, and we are pleased that Sigma innovation has played such a key role in its development. Applying our proprietary CompoZr ZFN technology in this very practical application has provided researchers with a powerful new tool to study human diseases. The potential applications using these rodent models of human disease could ultimately eliminate years of research time and save millions of lives," said Dr. Dave Smoller, President, Sigma Research Biotechnology.

For over a quarter century researchers have been trying to generate Knockout rats that closely mimic human diseases, a breakthrough now possible due to the gene-editing capabilities of ZFN technology, which is significant, as rats are highly characterized animals and physiologically similar to humans. Because their larger size makes them superior to mice in biological research applications, rats are ideal subjects for research into human diseases.

Sigma-Aldrich is the premiere resource for commercial zinc finger nucleases and markets its CompoZr ZFN products and services based on an exclusive partnership with Sangamo BioSciences. For more information on SAGE Labs or our gene-editing technologies, visit www.sigma.com/sagelabs.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich, Sigma, SAGE and CompoZr are trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
Breaking Biology Technology:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a ... intravenous (IV) therapy, today announced receipt of its ISO 13485 Certification, ... by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early ... "This is an ...
(Date:5/23/2017)... the first robotic gym for the rehabilitation and functional motor sense evaluation ... Genoa, Italy . The first 30 robots will be available from ... . The technology was developed and patented at the IIT laboratories ... Technology thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
Breaking Biology News(10 mins):